{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:15:45Z","timestamp":1790774145950,"version":"4.1.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,21]],"date-time":"2024-08-21T00:00:00Z","timestamp":1724198400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01-CA078902"],"award-info":[{"award-number":["P01-CA078902"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P01-CA018029"],"award-info":[{"award-number":["P01-CA018029"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA015704"],"award-info":[{"award-number":["P30-CA015704"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1038\/s41375-024-02378-5","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T15:33:39Z","timestamp":1724340819000},"page":"2266-2269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Optimal prognostic threshold for measurable residual disease positivity by multiparameter flow cytometry in acute myeloid leukemia (AML)"],"prefix":"10.1038","volume":"38","author":[{"given":"Eduardo","family":"Rodr\u00edguez-Arbol\u00ed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1869-180X","authenticated-orcid":false,"given":"Sylvie D.","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Buccisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0969-3766","authenticated-orcid":false,"given":"Lok Lam","family":"Ngai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2855-8121","authenticated-orcid":false,"given":"Raffaele","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Cloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Meddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nigel H.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Gradowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert J.","family":"Ossenkoppele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob","family":"L\u00f6wenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-3341","authenticated-orcid":false,"given":"Roland B.","family":"Walter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,21]]},"reference":[{"key":"2378_CR1","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","volume":"131","author":"GJ Schuurhuis","year":"2018","unstructured":"Schuurhuis GJ, Heuser M, Freeman S, B\u00e9n\u00e9 MC, Buccisano F, Cloos J, et al. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018;131:1275\u201391.","journal-title":"Blood"},{"key":"2378_CR2","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.1182\/blood.2021013626","volume":"138","author":"M Heuser","year":"2021","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ, Buccisano F, Hourigan CS, Ngai LL, et al. 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2021;138:2753\u201367.","journal-title":"Blood"},{"key":"2378_CR3","doi-asserted-by":"publisher","first-page":"e676","DOI":"10.1097\/HS9.0000000000000676","volume":"6","author":"JM Tettero","year":"2022","unstructured":"Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, et al. Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party. Hemasphere. 2022;6:e676.","journal-title":"Hemasphere"},{"key":"2378_CR4","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1182\/blood.V96.12.3948","volume":"96","author":"A Venditti","year":"2000","unstructured":"Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C, et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000;96:3948\u201352.","journal-title":"Blood"},{"key":"2378_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1038\/sj.leu.2404313","volume":"20","author":"F Buccisano","year":"2006","unstructured":"Buccisano F, Maurillo L, Gattei V, Del Poeta G, Del Principe MI, Cox MC, et al. The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. Leukemia. 2006;20:1783\u20139.","journal-title":"Leukemia"},{"key":"2378_CR6","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.1200\/JCO.2007.15.9814","volume":"26","author":"L Maurillo","year":"2008","unstructured":"Maurillo L, Buccisano F, Del Principe MI, Del Poeta G, Spagnoli A, Panetta P, et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol. 2008;26:4944\u201351.","journal-title":"J Clin Oncol"},{"key":"2378_CR7","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2009-12-258178","volume":"116","author":"F Buccisano","year":"2010","unstructured":"Buccisano F, Maurillo L, Spagnoli A, Del Principe MI, Fraboni D, Panetta P, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood. 2010;116:2295\u2013303.","journal-title":"Blood"},{"key":"2378_CR8","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1182\/blood.2021014804","volume":"139","author":"G Paras","year":"2022","unstructured":"Paras G, Morsink LM, Othus M, Milano F, Sandmaier BM, Zarling LC, et al. Conditioning intensity and peritransplant flow cytometric MRD dynamics in adult AML. Blood. 2022;139:1694\u2013706.","journal-title":"Blood"},{"key":"2378_CR9","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3324\/haematol.2022.281631","volume":"108","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2023","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Othus M, Orvain C, Zarling LC, Sandmaier BM, Milano F, et al. Contribution of measurable residual disease status to prediction accuracy of relapse and survival in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Haematologica. 2023;108:273\u20137.","journal-title":"Haematologica"},{"key":"2378_CR10","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1093\/biomet\/92.4.965","volume":"92","author":"M G\u00f6nen","year":"2005","unstructured":"G\u00f6nen M, Heller G. Concordance probability and discriminatory power in proportional hazards regression. Biometrika. 2005;92:965\u201370.","journal-title":"Biometrika"},{"key":"2378_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.2307\/2532740","volume":"48","author":"B Lausen","year":"1992","unstructured":"Lausen B, Schumacher M. Maximally selected rank statistics. Biometrics. 1992;48:73\u201385.","journal-title":"Biometrics"},{"key":"2378_CR12","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0167-9473(02)00225-6","volume":"43","author":"T Hothorn","year":"2003","unstructured":"Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Stat Data Anal. 2003;43:121\u201337.","journal-title":"Comput Stat Data Anal"},{"key":"2378_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/bimj.200310030","volume":"46","author":"B Lausen","year":"2004","unstructured":"Lausen B, Hothorn T, Bretz F, Schumacher M. Assessment of optimal selected prognostic factors. Biom J. 2004;46:364\u201374.","journal-title":"Biom J"},{"key":"2378_CR14","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","volume":"332","author":"DG Altman","year":"2006","unstructured":"Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332:1080.","journal-title":"BMJ"},{"key":"2378_CR15","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/s41409-019-0679-x","volume":"55","author":"J Gauthier","year":"2020","unstructured":"Gauthier J, Wu QV, Gooley TA. Cubic splines to model relationships between continuous variables and outcomes: a guide for clinicians. Bone Marrow Transpl. 2020;55:675\u201380.","journal-title":"Bone Marrow Transpl"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02378-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02378-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02378-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T11:06:29Z","timestamp":1727435189000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-024-02378-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2378"],"URL":"https:\/\/doi.org\/10.1038\/s41375-024-02378-5","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,21]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ERA has been a consultant to Astellas and Laboratoires Delbert, and received travel grants and\/or speaker fees from AbbVie, Astellas, Eurocept, Gilead, and Jazz Pharmaceuticals. MO has been a consultant to Biosight and Merck and served on Data Safety Monitoring Boards for Celgene\/Bristol Myers Squibb, Grifols, and Glycomimetics. SDF has been a consultant to MPAACT; institute research funding from Bristol Myers Squibb, and Jazz Pharmaceuticals. FB has been a consultant to Jazz Pharmaceuticals, Laboratoires Delbert, and Novartis, received research funding from Becton Dickinson, and received speaker fees from AbbVie, Astellas, Bristol Myers Squibb, Janssen-Cilag, and Jazz Pharmaceuticals. JC received speaker fees from Astellas; institute receives royalties from BD Biosciences and Navigate, and institute receives research funding from Genentech, Novartis, and Takeda. RBW received laboratory research grants and\/or clinical trial support from Aptevo, Celgene\/Bristol Myers Squibb, ImmunoGen\/AbbVie, Janssen, Jazz, Kite, Kura, Pfizer, and VOR, and has been a consultant to Wugen. All other authors declare no competing conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}